Efficacy and safety of lamivudine for treatment of chronic hepatitis B in renal allograft recipients.
Alavian
S M
SM
Department of Gastroenterology, Baghiatollah University of Medical Sciences, Tehran, Iran. sm_alavian@alavian-the.org
Hajarizadeh
B
B
Einollahi
B
B
D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016030:Kidney Transplantation / Q000276:immunology*; D019259:Lamivudine / Q000627:therapeutic use*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy / Q000821:virology*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D012449:Safety
D007166:Immunosuppressive Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine